Opko Health (NASDAQ:OPK)‘s stock had its “buy” rating reiterated by stock analysts at Barrington Research in a note issued to investors on Monday, November 12th. They currently have a $7.00 price objective on the biotechnology company’s stock. Barrington Research’s price objective would indicate a potential upside of 100.57% from the company’s previous close. Barrington Research also issued estimates for Opko Health’s FY2018 earnings at ($0.20) EPS, Q1 2019 earnings at ($0.05) EPS, Q2 2019 earnings at ($0.04) EPS, Q3 2019 earnings at ($0.04) EPS, FY2019 earnings at ($0.17) EPS, FY2020 earnings at ($0.02) EPS, FY2021 earnings at $0.11 EPS and FY2022 earnings at $0.31 EPS.
The analysts wrote, “We are maintaining our OUTPERFORM investment rating on OPK shares and our price target remains $7. We arrive at our price target via a DCF methodology for its current commercial business plus the hGH-CTP program. We assign an additional $1 of value for the rest of OPKO’s product pipeline.””
A number of other analysts have also weighed in on OPK. BidaskClub upgraded shares of Opko Health from a “buy” rating to a “strong-buy” rating in a research report on Friday, August 24th. ValuEngine upgraded shares of Opko Health from a “strong sell” rating to a “sell” rating in a research report on Thursday, August 2nd. Finally, Cantor Fitzgerald restated a “buy” rating and issued a $20.00 target price on shares of Opko Health in a research report on Tuesday, August 7th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $9.50.
Opko Health (NASDAQ:OPK) last posted its quarterly earnings results on Friday, November 9th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.08) by $0.03. The business had revenue of $250.00 million for the quarter, compared to analyst estimates of $264.04 million. Opko Health had a negative net margin of 30.24% and a negative return on equity of 8.68%. The firm’s revenue for the quarter was up 1.6% on a year-over-year basis. During the same quarter last year, the business posted ($0.08) EPS. Equities research analysts predict that Opko Health will post -0.21 earnings per share for the current fiscal year.
In other Opko Health news, CEO Phillip Md Et Al Frost purchased 10,000 shares of the business’s stock in a transaction dated Friday, September 7th. The shares were bought at an average price of $5.57 per share, for a total transaction of $55,700.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 42.74% of the stock is currently owned by insiders.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. increased its stake in Opko Health by 2.1% in the third quarter. Vanguard Group Inc. now owns 29,660,750 shares of the biotechnology company’s stock valued at $102,626,000 after purchasing an additional 614,442 shares in the last quarter. Teachers Advisors LLC increased its stake in Opko Health by 3.5% in the third quarter. Teachers Advisors LLC now owns 754,427 shares of the biotechnology company’s stock valued at $2,610,000 after purchasing an additional 25,222 shares in the last quarter. MetLife Investment Advisors LLC increased its stake in Opko Health by 38.2% in the third quarter. MetLife Investment Advisors LLC now owns 207,467 shares of the biotechnology company’s stock valued at $718,000 after purchasing an additional 57,299 shares in the last quarter. Pacer Advisors Inc. bought a new stake in Opko Health in the third quarter valued at $198,000. Finally, BlueMountain Capital Management LLC bought a new stake in Opko Health in the third quarter valued at $187,000. 26.20% of the stock is owned by institutional investors and hedge funds.
About Opko Health
OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates Bio-Reference Laboratories, a clinical laboratory that offers laboratory testing services in the detection, diagnosis, evaluation, monitoring, and treatment of diseases.
Recommended Story: Cash Flow
Receive News & Ratings for Opko Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health and related companies with MarketBeat.com's FREE daily email newsletter.